INSYS Therapeutics (INSY) Decline Appers Overdone - Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
INSYS Therapeutics (INSY) Stock Declines on Reports of Doctor Fraud
May 9, 2014 4:36 PM EDTINSYS Therapeutics (Nasdaq: INSY) stock tanked on reports a doctor in Michigan has been accused of defrauding Medicare by $7 million. The doctor is accused of writing 1,283 million prescriptions for Subsys in 5 years, 20.3% of Subsys prescribed to Medicare beneficiaries nationwide during this... More
